Literature DB >> 27050632

Doing the math on hepatitis C virus treatment.

Shruti H Mehta1, David L Thomas2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27050632      PMCID： PMC4912864          DOI： 10.1016/j.jhep.2016.03.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  13 in total

1.  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2012-03-20       Impact factor: 25.083

2.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2013-12-09       Impact factor: 25.083

3.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Authors:  Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-11       Impact factor: 11.382

Review 4.  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Authors: 
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

5.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

6.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

Authors:  Fred Poordad; Christophe Hezode; Roger Trinh; Kris V Kowdley; Stefan Zeuzem; Kosh Agarwal; Mitchell L Shiffman; Heiner Wedemeyer; Thomas Berg; Eric M Yoshida; Xavier Forns; Sandra S Lovell; Barbara Da Silva-Tillmann; Christine A Collins; Andrew L Campbell; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

7.  Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.

Authors:  Zobair M Younossi; Mendel E Singer; Heshaam M Mir; Linda Henry; Sharon Hunt
Journal:  J Hepatol       Date:  2013-11-19       Impact factor: 25.083

8.  Exceeding the limits of liver histology markers.

Authors:  Shruti H Mehta; Bryan Lau; Nezam H Afdhal; David L Thomas
Journal:  J Hepatol       Date:  2008-10-18       Impact factor: 25.083

9.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

Review 10.  Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.

Authors:  Rebecca L Morgan; Brittney Baack; Bryce D Smith; Anthony Yartel; Marc Pitasi; Yngve Falck-Ytter
Journal:  Ann Intern Med       Date:  2013-03-05       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.